Proxy Votes Now

Home › Activist investors › Wynnefield Capital

Wynnefield Capital

Campaign activist. Positions and campaigns from Wynnefield Capital’s SEC filings. Updated November 20, 2026.

Filer entities
WYNNEFIELD CAPITAL INC
SEC CIK
1251567 (WYNNEFIELD CAPITAL INC)
SEC filings
Schedule 13D filings · 13F reports · soliciting material
Latest 13F
Quarter ended Sep 30, 2026, filed Nov 16, 2026: 8 US-listed positions reported; 4 of 1% or more of a company without a 13D are listed below.
6current positions
1new or changed in 90 days
0active campaigns
2campaigns on record

Active campaigns

No active campaign by this definition (see How to read this).

Current positions (6)

CompanyStakeSourceFirst disclosedLast changeSince previous filingFlagsStated intent
Lifecore Biomedical, Inc. 14.3%5,512,210 shares Schedule 13D/A, filed Sep 29, 2026 Sep 29, 2026 Increased Sep 29, 2026 ▼ 1.70 pts New Seeks changes or engagement
DLH Holdings Corp. 25.40%3,681,421 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Jul 28, 2026 May 15, 2014 — 0.00 pts — 13F: none stated
Nature's Sunshine Products, Inc. 14.28%2,473,686 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 23, 2026 May 15, 2014 — ▲ 0.22 pts — 13F: none stated
Quest Resource Holding Corp 13.3%2,734,349 shares Schedule 13D, filed May 8, 2025 May 8, 2025 — — — Seeks changes or engagement
TechPrecision Corporation 4.29%433,605 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Aug 6, 2026 Nov 14, 2023 — ▼ 0.03 pts — 13F: none stated
Cadre Holdings, Inc. 2.81%1,205,000 shares 13F, quarter ended Sep 30, 2026filed Nov 16, 2026; % of shares outstanding as of Oct 30, 2026 Feb 14, 2022 — ▼ 0.01 pts — 13F: none stated

Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.

Stated intent (13D Item 4)

Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.

Lifecore Biomedical, Inc. · Seeks changes or engagement

“…Agreement (the "Support Agreement") with Lifecore, Inc., a Delaware corporation ("Parent"), and the Issuer in connection with the Agreement and Plan of Merger, dated as of September 27, 2026, among Parent, Hazel Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent ("Merger Sub"), and the Issuer (the "Merger Agreement"). The Merger Agreement provides, among other things and subject to its terms and conditions, for the…”

Item 4 in the Schedule 13D/A filed Sep 29, 2026.

Summary of the filing Wynnefield Partners, an existing board-seat holder at Lifecore, signed a support agreement to vote its shares for the company's pending merger with Lifecore, Inc.

Quoted from the filing (item 4): “On September 27, 2026, the Wynnefield Reporting Persons entered into a Voting and Support Agreement (the "Support Agreement") with Lifecore, Inc., a Delaware corporation ("Parent"), and the Issuer in connection with the Agreement and Plan of Merger, dated as of September 27, 2026” Sep 29, 2026

Quest Resource Holding Corp · Seeks changes or engagement

“On May 7, 2025, the Wynnefield Reporting Persons entered into a Cooperation Agreement (the " Cooperation Agreement") with the Issuer. Pursuant to the terms of the Cooperation Agreement, the Board of Directors of the Issuer (the "Board") agreed to expand the size of the Board by one member and appoint Robert Lipstein (the "New Director") to the Board as a Class III…”

Item 4 in the Schedule 13D filed May 8, 2025.

Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.

Past campaigns (2)
CompanyOutcome or last statusDateFirst filingHighest stageFilingsMeeting / votes
Quest Resource Holding Corp Settled (agreement with the company) May 8, 2025 May 8, 2025 — latest (2) —
Lifecore Biomedical, Inc. Settled (agreement with the company) Jul 1, 2024 Jul 1, 2024 — latest (1) —

How large managers voted in Wynnefield Capital’s proxy contests (meetings since July 2023)

Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.

No proxy contest has gone to a vote since July 1, 2023.

Track record

How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.

2Settlement
Outcome of each campaign (2)
CompanyOutcomeDetailDateFirst filing
Quest Resource Holding Corp Settlement agreement with the company May 8, 2025 May 8, 2025
Lifecore Biomedical, Inc. Settlement agreement with the company Jul 1, 2024 Jul 1, 2024

Share price after the first 13D

The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 1 of 2 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).

CompanyFirst 13DTo latest closeSPY same dates6 months after12 months after
Lifecore Biomedical, Inc. LFCR Sep 29, 2026 -2.9%Sep 29, 2026 – Nov 18, 2026 -4.4% not yet / no price not yet / no price

Prices: daily closes (Nasdaq), as stored by the site.

Settlement terms

Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.

Lifecore Biomedical, Inc. · Jul 1, 2024 · Directors named, Voting commitment

Other disclosed holders around the same time

Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Wynnefield Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.

Lifecore Biomedical, Inc. · Wynnefield Capital first disclosed Sep 29, 2026 · 1 other filing
HolderFormDateStake
BlackRock, Inc. Schedule 13G Apr 27, 2026 5.0%

How to read this

Flags (last 90 days)
New first disclosed in the last 90 days. Increased / Decreased shares up or down in a 13D/A or 13F filed in that time. Below 5% a 13D/A reported less than 5%, the reporting threshold. Exited a 13D/A reported no shares, or the investor’s 13F no longer lists a company it listed before.
Active campaign
A contested meeting at which the investor is soliciting proxies is still to be held; or in the last 12 months it filed a proxy-contest document (PREC14A, DEFC14A or DFAN14A soliciting material), stated in a 13D that it nominated directors, filed a letter or presentation to the board or shareholders, or stated public demands in a 13D — and no settlement, withdrawal, contested vote or 13D below 5% is dated on or after the latest such filing. Status is the furthest step since then: Public demands in a 13D < Public letter or soliciting material < Nominations made < Proxy contest filed.
Sources and limits
SEC EDGAR only. 13D data covers filings since June 2023; 13F reports are quarterly and filed up to 45 days after the quarter, and do not show swaps, most options or non-US holdings. Settlements are cooperation agreements disclosed in the company’s 8-K or stated in the investor’s 13D; board seats are read from the 8-K. Text marked Summary of the filing is checked against the filing, whose words are quoted beside it. Nothing on this page predicts what the investor will do.